You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePaclitaxel
Accession NumberDB01229  (APRD00259, DB05261, DB05927)
TypeSmall Molecule
GroupsApproved, Vet Approved
DescriptionPaclitaxel is a mitotic inhibitor used in cancer chemotherapy. It was discovered in a US National Cancer Institute program at the Research Triangle Institute in 1967 when Monroe E. Wall and Mansukh C. Wani isolated it from the bark of the Pacific yew tree, Taxus brevifolia and named it taxol. Later it was discovered that endophytic fungi in the bark synthesize paclitaxel. When it was developed commercially by Bristol-Myers Squibb (BMS), the generic name was changed to paclitaxel and the BMS compound is sold under the trademark Taxol. In this formulation, paclitaxel is dissolved in Kolliphor EL and ethanol, as a delivery agent. A newer formulation, in which paclitaxel is bound to albumin, is sold under the trademark Abraxane. [Wikipedia]
Structure
Thumb
Synonyms
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
Paclitaxel
Taxol
Taxol A
External Identifiers
  • ABI-007
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AbraxanePowder for suspension for infusion5 mg/mlIntravenous useCelgene Europe Ltd  2008-01-11Not applicableEu
AbraxanePowder for suspension for infusion5 mg/mlIntravenous useCelgene Europe Ltd  2008-01-11Not applicableEu
Abraxaneinjection, powder, lyophilized, for suspension100 mg/20mLintravenousAbraxis Bio Science, Llc2005-02-10Not applicableUs
Abraxane for Injectable Suspensionpowder for suspension100 mgintravenousCelgene Inc2006-08-31Not applicableCanada
Aj-paclitaxelsolution6 mgintravenousAgila Jamp Canada IncNot applicableNot applicableCanada
Paclitaxelinjection6 mg/mLintravenousWG Critical Care, LLC2013-07-11Not applicableUs
Paclitaxelliquid6 mgintravenousIvax Pharmaceuticals IncorporatedNot applicableNot applicableCanada
Paclitaxelinjection6 mg/mLintravenousWG Critical Care, LLC2013-07-11Not applicableUs
Paclitaxelinjection6 mg/mLintravenousWG Critical Care, LLC2013-07-11Not applicableUs
Paclitaxel for Injectionsolution6 mgintravenousBiolyse Pharma Corporation2001-10-31Not applicableCanada
Paclitaxel for Injectionsolution6 mgintravenousHospira Healthcare Corporation2007-12-17Not applicableCanada
Paclitaxel for Injectionsolution6 mgintravenousTeva Canada LimitedNot applicableNot applicableCanada
Paclitaxel for Injection USPsolution6 mgintravenousSterimax Inc2011-02-22Not applicableCanada
Paclitaxel Injectionliquid6 mgintravenousImmunex Corporation1997-10-242005-12-06Canada
Paclitaxel Injectionliquid6 mgintravenousDraxis Health Inc.Not applicableNot applicableCanada
Paclitaxel Injection USPsolution6 mgintravenousSandoz Canada Incorporated2015-03-31Not applicableCanada
Paclitaxel Injection USPsolution6 mgintravenousAccord Healthcare Inc2014-07-02Not applicableCanada
Paclitaxel Injection, USPsolution6 mgintravenousMylan Pharmaceuticals UlcNot applicableNot applicableCanada
Paxeneliquid6 mgintravenousBaker Norton Pharmaceuticals Inc.Not applicableNot applicableCanada
Taxolsolution6 mgintravenousBristol Myers Squibb Canada1993-12-312012-07-20Canada
Teva-paclitaxel for Injectionliquid6 mgintravenousTeva Canada LimitedNot applicableNot applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-paclitaxel Injectablesolution6 mgintravenousApotex Inc2005-02-07Not applicableCanada
Paclitaxelinjection, solution6 mg/mLintravenousSagent Pharmaceuticals2011-09-27Not applicableUs
Paclitaxelinjection100 mg/16.7mLintravenousPfizer Laboratories Div Pfizer Inc.2011-09-30Not applicableUs
Paclitaxelinjection, solution6 mg/mLintravenousSandoz Inc2008-01-02Not applicableUs
Paclitaxelinjection, solution, concentrate6 mg/mLintravenousTeva Parenteral Medicines, Inc.2008-09-24Not applicableUs
Paclitaxelinjection, solution6 mg/mLintravenousActavis Pharma, Inc.2015-01-05Not applicableUs
Paclitaxelinjection300 mg/50mLintravenousPfizer Laboratories Div Pfizer Inc.2011-09-30Not applicableUs
Paclitaxelinjection300 mg/50mLintravenousMylan Institutional LLC2011-09-30Not applicableUs
Paclitaxelinjection, solution, concentrate6 mg/mLintravenousTeva Parenteral Medicines, Inc.2008-10-23Not applicableUs
Paclitaxelinjection, solution6 mg/mLintravenousHospira Worldwide, Inc.2002-05-08Not applicableUs
Paclitaxelinjection30 mg/5mLintravenousPfizer Laboratories Div Pfizer Inc.2011-09-30Not applicableUs
Paclitaxelinjection100 mg/16.7mLintravenousMylan Institutional LLC2011-09-30Not applicableUs
Paclitaxelinjection, solution, concentrate6 mg/mLintravenousTeva Parenteral Medicines, Inc.2009-09-16Not applicableUs
Paclitaxelinjection, solution6 mg/mLintravenousFresenius Kabi USA, LLC2009-03-20Not applicableUs
Paclitaxelinjection, solution, concentrate6 mg/mLintravenousTeva Parenteral Medicines, Inc.2009-11-03Not applicableUs
Paclitaxelinjection30 mg/5mLintravenousMylan Institutional LLC2011-09-30Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
PaxeneConcentrate for solution for infusion6 mg/mlIntravenous useNorton Healthcare Ltd.1999-07-19Not applicableEu
PaxeneConcentrate for solution for infusion6 mg/mlIntravenous useNorton Healthcare Ltd.1999-07-19Not applicableEu
PaxeneConcentrate for solution for infusion6 mg/mlIntravenous useNorton Healthcare Ltd.1999-07-19Not applicableEu
PaxeneConcentrate for solution for infusion 16 mg/mlIntravenous useNorton Healthcare Ltd.1999-07-19Not applicableEu
International Brands
NameCompany
OnxolNot Available
PaxceedNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIP88XT4IS4D
CAS number33069-62-4
WeightAverage: 853.9061
Monoisotopic: 853.330955345
Chemical FormulaC47H51NO14
InChI KeyInChIKey=RCINICONZNJXQF-MZXODVADSA-N
InChI
InChI=1S/C47H51NO14/c1-25-31(60-43(56)36(52)35(28-16-10-7-11-17-28)48-41(54)29-18-12-8-13-19-29)23-47(57)40(61-42(55)30-20-14-9-15-21-30)38-45(6,32(51)22-33-46(38,24-58-33)62-27(3)50)39(53)37(59-26(2)49)34(25)44(47,4)5/h7-21,31-33,35-38,40,51-52,57H,22-24H2,1-6H3,(H,48,54)/t31-,32-,33+,35-,36+,37+,38-,40-,45+,46-,47+/m0/s1
IUPAC Name
(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-bis(acetyloxy)-1,9-dihydroxy-15-{[(2R,3S)-2-hydroxy-3-phenyl-3-(phenylformamido)propanoyl]oxy}-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.0³,¹⁰.0⁴,⁷]heptadec-13-en-2-yl benzoate
SMILES
[H][C@]12[[email protected]](OC(=O)C3=CC=CC=C3)[C@]3(O)C[[email protected]](OC(=O)[[email protected]](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[[email protected]]1OC[C@@]21OC(C)=O)C3(C)C
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as taxanes and derivatives. These are diterpenoids with a structure based either on the taxane skeleton, or a derivative thereof. In term of phytochemistry, several derivatives of the taxane skeleton exist
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassPrenol lipids
Sub ClassDiterpenoids
Direct ParentTaxanes and derivatives
Alternative Parents
Substituents
  • Taxane diterpenoid
  • N-benzylbenzamide
  • Beta amino acid or derivatives
  • Phenylpropylamine
  • Benzoate ester
  • Benzylether
  • Benzoic acid or derivatives
  • Benzamide
  • Benzoyl
  • Alpha-acyloxy ketone
  • Fatty acid ester
  • Fatty acyl
  • Benzenoid
  • Monosaccharide
  • Dicarboxylic acid or derivatives
  • Monocyclic benzene moiety
  • Acetate salt
  • Tertiary alcohol
  • Cyclic alcohol
  • Secondary carboxylic acid amide
  • Secondary alcohol
  • Oxetane
  • Ketone
  • Carboxylic acid ester
  • Carboxamide group
  • Oxacycle
  • Organoheterocyclic compound
  • Ether
  • Dialkyl ether
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Alcohol
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationUsed in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.
PharmacodynamicsPaclitaxel is a taxoid antineoplastic agent indicated as first-line and subsequent therapy for the treatment of advanced carcinoma of the ovary, and other various cancers including breast cancer. Paclitaxel is a novel antimicrotubule agent that promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization. This stability results in the inhibition of the normal dynamic reorganization of the microtubule network that is essential for vital interphase and mitotic cellular functions. In addition, paclitaxel induces abnormal arrays or "bundles" of microtubules throughout the cell cycle and multiple asters of microtubules during mitosis.
Mechanism of actionPaclitaxel interferes with the normal function of microtubule growth. Whereas drugs like colchicine cause the depolymerization of microtubules in vivo, paclitaxel arrests their function by having the opposite effect; it hyper-stabilizes their structure. This destroys the cell's ability to use its cytoskeleton in a flexible manner. Specifically, paclitaxel binds to the β subunit of tubulin. Tubulin is the "building block" of mictotubules, and the binding of paclitaxel locks these building blocks in place. The resulting microtubule/paclitaxel complex does not have the ability to disassemble. This adversely affects cell function because the shortening and lengthening of microtubules (termed dynamic instability) is necessary for their function as a transportation highway for the cell. Chromosomes, for example, rely upon this property of microtubules during mitosis. Further research has indicated that paclitaxel induces programmed cell death (apoptosis) in cancer cells by binding to an apoptosis stopping protein called Bcl-2 (B-cell leukemia 2) and thus arresting its function.
Related Articles
AbsorptionWhen a 24 hour infusion of 135 mg/m^2 is given to ovarian cancer patients, the maximum plasma concentration (Cmax) is 195 ng/mL, while the AUC is 6300 ng•h/mL.
Volume of distribution
  • 227 to 688 L/m^2 [apparent volume of distribution at steady-state, 24 hour infusion]
Protein binding89%-98% bound to plasma protein. The presence of cimetidine, ranitidine, dexamethasone, or diphenhydramine did not affect protein binding of paclitaxel.
Metabolism

Hepatic. In vitro studies with human liver microsomes and tissue slices showed that paclitaxel was metabolized primarily to 6a-hydrox-ypaclitaxel by the cytochrome P450 isozyme CYP2C8; and to two minor metabolites, 3’-p-hydroxypaclitaxel and 6a, 3’-p-dihydroxypaclitaxel, by CYP3A4.

SubstrateEnzymesProduct
Paclitaxel
Not Available
3'-p-hydroxypaclitaxelDetails
Paclitaxel
Not Available
6a-hydrox-ypaclitaxelDetails
Paclitaxel
Not Available
6a, 3'-p-dihydroxypaclitaxelDetails
Route of eliminationIn 5 patients administered a 225 or 250 mg/m2 dose of radiolabeled paclitaxel as a 3-hour infusion, a mean of 71% of the radioactivity was excreted in the feces in 120 hours, and 14% was recovered in the urine.
Half lifeWhen a 24 hour infusion of 135 mg/m^2 is given to ovarian cancer patients, the elimination half=life is 52.7 hours.
Clearance
  • 21.7 L/h/m2 [Dose 135 mg/m2, infusion duration 24 h]
  • 23.8 L/h/m2 [Dose 175 mg/m2, infusion duration 24 h]
  • 7 L/h/m2 [Dose 135 mg/m2, infusion duration 3 h]
  • 12.2 L/h/m2 [Dose 175 mg/m2, infusion duration 3 h]
ToxicityRat (ipr) LD50=32530 µg/kg. Symptoms of overdose include bone marrow suppression, peripheral neurotoxicity, and mucositis. Overdoses in pediatric patients may be associated with acute ethanol toxicity.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Paclitaxel Action PathwayDrug actionSMP00434
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.914
Blood Brain Barrier-0.9748
Caco-2 permeable-0.8957
P-glycoprotein substrateSubstrate0.8345
P-glycoprotein inhibitor IInhibitor0.5509
P-glycoprotein inhibitor IINon-inhibitor0.7309
Renal organic cation transporterNon-inhibitor0.9349
CYP450 2C9 substrateNon-substrate0.837
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.7278
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8937
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.9158
BiodegradationNot ready biodegradable0.9491
Rat acute toxicity2.4391 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9978
hERG inhibition (predictor II)Non-inhibitor0.7982
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Injection, powder, lyophilized, for suspensionintravenous100 mg/20mL
Powder for suspension for infusionIntravenous use5 mg/ml
Powder for suspensionintravenous100 mg
Injectionintravenous100 mg/16.7mL
Injectionintravenous30 mg/5mL
Injectionintravenous300 mg/50mL
Injectionintravenous6 mg/mL
Injection, solutionintravenous6 mg/mL
Injection, solution, concentrateintravenous6 mg/mL
Solutionintravenous6 mg
Liquidintravenous6 mg
Concentrate for solution for infusionIntravenous use6 mg/ml
Concentrate for solution for infusion 1Intravenous use6 mg/ml
Prices
Unit descriptionCostUnit
Abraxane 100 mg vial1119.6USD vial
Taxol 30 mg/5 ml vial35.06USD ml
Onxol 30 mg/5 ml vial34.54USD ml
Onxol 300 mg/50 ml vial34.54USD ml
Paclitaxel 300 mg/50 ml vial5.31USD ml
Paclitaxel 100 mg/16.7 ml vial4.45USD ml
Paclitaxel 30 mg/5 ml vial3.54USD ml
Paclitaxel 150 mg/25 ml vial3.36USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2086874 No1998-09-012013-01-07Canada
CA2155947 No2007-08-212014-02-22Canada
US5439686 No1993-02-222013-02-22Us
US5498421 No1993-03-122013-03-12Us
US7758891 No2006-02-212026-02-21Us
US7820788 No2004-10-272024-10-27Us
US7923536 No2003-12-092023-12-09Us
US8034375 No2006-08-132026-08-13Us
US8138229 No2003-12-092023-12-09Us
US8268348 No2006-02-212026-02-21Us
US8314156 No2003-12-092023-12-09Us
US8853260 No2000-10-102020-10-10Us
US9101543 No2006-02-212026-02-21Us
USRE41884 No1996-08-142016-08-14Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point216-217 °CFDA label
water solubilityInsolubleFDA label
logP3Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00556 mg/mLALOGPS
logP3.2ALOGPS
logP3.54ChemAxon
logS-5.2ALOGPS
pKa (Strongest Acidic)10.36ChemAxon
pKa (Strongest Basic)-1ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count10ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area221.29 Å2ChemAxon
Rotatable Bond Count14ChemAxon
Refractivity218.29 m3·mol-1ChemAxon
Polarizability87.17 Å3ChemAxon
Number of Rings7ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Hendricus B. A. de Bont, Ruben G. G. Leenders, Johan W. Scheeren, Hidde J. Haisma, Dick de Vos, “Paclitaxel prodrugs, method for preparation as well as their use in selective chemotherapy.” U.S. Patent US5760072, issued September, 1989.

US5760072
General References
  1. Wall ME, Wani MC: Camptothecin and taxol: discovery to clinic--thirteenth Bruce F. Cain Memorial Award Lecture. Cancer Res. 1995 Feb 15;55(4):753-60. [PubMed:7850785 ]
  2. Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT: Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc. 1971 May 5;93(9):2325-7. [PubMed:5553076 ]
  3. Fuchs DA, Johnson RK: Cytologic evidence that taxol, an antineoplastic agent from Taxus brevifolia, acts as a mitotic spindle poison. Cancer Treat Rep. 1978 Aug;62(8):1219-22. [PubMed:688258 ]
  4. Saville MW, Lietzau J, Pluda JM, Feuerstein I, Odom J, Wilson WH, Humphrey RW, Feigal E, Steinberg SM, Broder S, et al.: Treatment of HIV-associated Kaposi's sarcoma with paclitaxel. Lancet. 1995 Jul 1;346(8966):26-8. [PubMed:7603142 ]
  5. Authors unspecified: ABI 007. Drugs R D. 2004;5(3):155-9. [PubMed:15139776 ]
  6. Gaitanis A, Staal S: Liposomal doxorubicin and nab-paclitaxel: nanoparticle cancer chemotherapy in current clinical use. Methods Mol Biol. 2010;624:385-92. doi: 10.1007/978-1-60761-609-2_26. [PubMed:20217610 ]
External Links
ATC CodesL01CD01
AHFS Codes
  • 10:00.00
PDB EntriesNot Available
FDA labelDownload (220 KB)
MSDSDownload (74 KB)
Interactions
Drug Interactions
Drug
2-(4-Chlorophenyl)-5-QuinoxalinecarboxamideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide.
2-MethoxyestradiolThe risk or severity of adverse effects can be increased when Paclitaxel is combined with 2-Methoxyestradiol.
3-MethoxybenzamideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with 3-Methoxybenzamide.
3,4-Dihydroxybenzoic AcidThe risk or severity of adverse effects can be increased when Paclitaxel is combined with 3,4-Dihydroxybenzoic Acid.
5,10-Dideazatetrahydrofolic AcidThe risk or severity of adverse effects can be increased when Paclitaxel is combined with 5,10-Dideazatetrahydrofolic Acid.
7-HydroxystaurosporineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with 7-Hydroxystaurosporine.
8-azaguanineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with 8-azaguanine.
9-(2-phosphonylmethoxyethyl)-2,6-diaminopurineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine.
AbirateroneThe serum concentration of Paclitaxel can be increased when it is combined with Abiraterone.
AbirateroneThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Abiraterone.
ABT-263The risk or severity of adverse effects can be increased when Paclitaxel is combined with ABT-263.
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Paclitaxel.
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Paclitaxel.
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Paclitaxel.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Paclitaxel.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Paclitaxel.
AfimoxifeneThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Afimoxifene.
AfliberceptThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Aflibercept.
AlatrofloxacinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Alatrofloxacin.
AlbendazoleThe serum concentration of Paclitaxel can be increased when it is combined with Albendazole.
AlbendazoleThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Albendazole.
AldesleukinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Aldesleukin.
AldosteroneThe serum concentration of Paclitaxel can be decreased when it is combined with Aldosterone.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Paclitaxel.
AlectinibThe serum concentration of Paclitaxel can be increased when it is combined with Alectinib.
AlemtuzumabThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Alemtuzumab.
AlfentanilThe serum concentration of Paclitaxel can be increased when it is combined with Alfentanil.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Paclitaxel.
Alpha-DifluoromethylornithineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Alpha-Difluoromethylornithine.
AltretamineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Altretamine.
AmantadineThe serum concentration of Paclitaxel can be increased when it is combined with Amantadine.
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Paclitaxel.
AminoglutethimideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Aminoglutethimide.
Aminohippuric acidThe serum concentration of Paclitaxel can be increased when it is combined with Aminohippuric acid.
Aminolevulinic acidThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Aminolevulinic acid.
AmiodaroneThe serum concentration of Paclitaxel can be decreased when it is combined with Amiodarone.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Paclitaxel.
AmlodipineThe serum concentration of Paclitaxel can be increased when it is combined with Amlodipine.
AmonafideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Amonafide.
AmprenavirThe serum concentration of Paclitaxel can be decreased when it is combined with Amprenavir.
AmrubicinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Amrubicin.
AmsacrineThe serum concentration of Paclitaxel can be increased when it is combined with Amsacrine.
AmsacrineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Amsacrine.
AnagrelideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Anagrelide.
AnastrozoleThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Anastrozole.
annamycinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with annamycin.
AP 12009The risk or severity of adverse effects can be increased when Paclitaxel is combined with AP 12009.
AP24534The risk or severity of adverse effects can be increased when Paclitaxel is combined with AP24534.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Paclitaxel.
AprepitantThe serum concentration of Paclitaxel can be increased when it is combined with Aprepitant.
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Paclitaxel.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Paclitaxel.
ASA404The risk or severity of adverse effects can be increased when Paclitaxel is combined with ASA404.
AsparaginaseThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Asparaginase.
AstemizoleThe serum concentration of Paclitaxel can be increased when it is combined with Astemizole.
AT-101The risk or severity of adverse effects can be increased when Paclitaxel is combined with AT-101.
AtazanavirThe serum concentration of Paclitaxel can be increased when it is combined with Atazanavir.
AtenololThe serum concentration of Atenolol can be increased when it is combined with Paclitaxel.
AtomoxetineThe metabolism of Paclitaxel can be decreased when combined with Atomoxetine.
AtorvastatinThe serum concentration of Paclitaxel can be increased when it is combined with Atorvastatin.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Paclitaxel.
AzacitidineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Azacitidine.
AzathioprineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Azathioprine.
AZD2171The risk or severity of adverse effects can be increased when Paclitaxel is combined with AZD2171.
Azelaic AcidThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Azelaic Acid.
AzelastineThe serum concentration of Paclitaxel can be increased when it is combined with Azelastine.
AzithromycinThe serum concentration of Paclitaxel can be increased when it is combined with Azithromycin.
BatimastatThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Batimastat.
BelinostatThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Belinostat.
BendamustineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Bendamustine.
BenzocaineThe serum concentration of Paclitaxel can be increased when it is combined with Benzocaine.
BepridilThe serum concentration of Paclitaxel can be increased when it is combined with Bepridil.
BesifloxacinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Besifloxacin.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Paclitaxel.
BevacizumabBevacizumab may increase the cardiotoxic activities of Paclitaxel.
BevacizumabThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Bevacizumab.
BexaroteneThe serum concentration of Bexarotene can be increased when it is combined with Paclitaxel.
BexaroteneThe serum concentration of Paclitaxel can be decreased when it is combined with Bexarotene.
BicalutamideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Bicalutamide.
BiperidenThe serum concentration of Paclitaxel can be increased when it is combined with Biperiden.
BleomycinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Bleomycin.
BlinatumomabThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Blinatumomab.
BoceprevirThe metabolism of Paclitaxel can be decreased when combined with Boceprevir.
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Paclitaxel.
BortezomibThe metabolism of Paclitaxel can be decreased when combined with Bortezomib.
BortezomibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Bortezomib.
BosentanThe serum concentration of Paclitaxel can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Paclitaxel.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Paclitaxel.
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Paclitaxel.
BSI-201The risk or severity of adverse effects can be increased when Paclitaxel is combined with BSI-201.
BuprenorphineThe serum concentration of Paclitaxel can be increased when it is combined with Buprenorphine.
BuspironeThe serum concentration of Paclitaxel can be increased when it is combined with Buspirone.
BusulfanThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Busulfan.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Paclitaxel.
CabergolineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Cabergoline.
CabozantinibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Cabozantinib.
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Paclitaxel.
CalcipotriolThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Calcipotriol.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Paclitaxel.
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Paclitaxel.
CandesartanThe serum concentration of Paclitaxel can be increased when it is combined with Candesartan.
CapecitabineThe metabolism of Paclitaxel can be decreased when combined with Capecitabine.
CapecitabineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Capecitabine.
CaptoprilThe serum concentration of Paclitaxel can be increased when it is combined with Captopril.
CarbamazepineThe serum concentration of Paclitaxel can be decreased when it is combined with Carbamazepine.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Paclitaxel.
CarboplatinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Carboplatin.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Paclitaxel.
CarmofurThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Carmofur.
CarmustineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Carmustine.
CarvedilolThe serum concentration of Paclitaxel can be increased when it is combined with Carvedilol.
CaspofunginThe serum concentration of Paclitaxel can be increased when it is combined with Caspofungin.
CatumaxomabThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Catumaxomab.
CB1954The risk or severity of adverse effects can be increased when Paclitaxel is combined with CB1954.
CelecoxibThe metabolism of Paclitaxel can be decreased when combined with Celecoxib.
CelecoxibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Celecoxib.
CeritinibThe serum concentration of Paclitaxel can be increased when it is combined with Ceritinib.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Paclitaxel.
CetuximabThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Cetuximab.
ChlorambucilThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Chlorambucil.
ChloroquineThe serum concentration of Paclitaxel can be increased when it is combined with Chloroquine.
ChlorotrianiseneThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Chlorotrianisene.
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Paclitaxel.
ChlorpropamideThe serum concentration of Paclitaxel can be increased when it is combined with Chlorpropamide.
ChlorprothixeneThe serum concentration of Paclitaxel can be increased when it is combined with Chlorprothixene.
CholecalciferolThe metabolism of Paclitaxel can be decreased when combined with Cholecalciferol.
CholesterolThe serum concentration of Paclitaxel can be increased when it is combined with Cholesterol.
Cholic AcidThe serum concentration of Paclitaxel can be decreased when it is combined with Cholic Acid.
CilazaprilThe serum concentration of Paclitaxel can be increased when it is combined with Cilazapril.
CimetidineThe serum concentration of Paclitaxel can be decreased when it is combined with Cimetidine.
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Paclitaxel.
CinoxacinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Cinoxacin.
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Paclitaxel.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Paclitaxel.
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Paclitaxel.
CladribineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Cladribine.
ClarithromycinThe serum concentration of Clarithromycin can be increased when it is combined with Paclitaxel.
ClemastineThe metabolism of Paclitaxel can be decreased when combined with Clemastine.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Paclitaxel.
ClofarabineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Clofarabine.
ClofazimineThe serum concentration of Paclitaxel can be increased when it is combined with Clofazimine.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Paclitaxel.
ClomipramineThe serum concentration of Paclitaxel can be increased when it is combined with Clomipramine.
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Paclitaxel.
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Paclitaxel.
ClopidogrelThe metabolism of Paclitaxel can be decreased when combined with Clopidogrel.
ClotrimazoleThe metabolism of Paclitaxel can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Clozapine.
CobicistatThe serum concentration of Paclitaxel can be increased when it is combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Paclitaxel.
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Paclitaxel.
ColforsinThe serum concentration of Paclitaxel can be increased when it is combined with Colforsin.
ConivaptanThe serum concentration of Paclitaxel can be increased when it is combined with Conivaptan.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Paclitaxel.
CrizotinibThe metabolism of Paclitaxel can be decreased when combined with Crizotinib.
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Paclitaxel.
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Paclitaxel.
CyclophosphamideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Cyclophosphamide.
CyclosporineThe metabolism of Paclitaxel can be decreased when combined with Cyclosporine.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Paclitaxel.
Cyproterone acetateThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Cyproterone acetate.
CytarabineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Cytarabine.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Paclitaxel.
DabrafenibThe serum concentration of Paclitaxel can be decreased when it is combined with Dabrafenib.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Paclitaxel.
DacarbazineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Dacarbazine.
DaclatasvirThe serum concentration of Paclitaxel can be increased when it is combined with Daclatasvir.
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Paclitaxel.
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Paclitaxel.
DaratumumabThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Daratumumab.
DarunavirThe metabolism of Paclitaxel can be decreased when combined with Darunavir.
DasatinibThe serum concentration of Paclitaxel can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Paclitaxel can be decreased when it is combined with Daunorubicin.
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Paclitaxel.
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Paclitaxel.
DecitabineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Decitabine.
DeferasiroxThe serum concentration of Paclitaxel can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Paclitaxel can be decreased when combined with Delavirdine.
Denileukin diftitoxThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Denileukin diftitox.
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Paclitaxel.
DesipramineThe serum concentration of Paclitaxel can be increased when it is combined with Desipramine.
DeslanosideDeslanoside may decrease the cardiotoxic activities of Paclitaxel.
DesloratadineThe serum concentration of Paclitaxel can be increased when it is combined with Desloratadine.
DexamethasoneThe serum concentration of Paclitaxel can be decreased when it is combined with Dexamethasone.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Paclitaxel.
DexrazoxaneThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Dexrazoxane.
DextromethorphanThe serum concentration of Paclitaxel can be increased when it is combined with Dextromethorphan.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Paclitaxel.
DiclofenacThe serum concentration of Paclitaxel can be increased when it is combined with Diclofenac.
DienogestThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Dienogest.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Paclitaxel.
DigitoxinDigitoxin may decrease the cardiotoxic activities of Paclitaxel.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Paclitaxel.
DigoxinDigoxin may decrease the cardiotoxic activities of Paclitaxel.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Paclitaxel.
DihydroergotamineThe metabolism of Paclitaxel can be decreased when combined with Dihydroergotamine.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Paclitaxel.
DiltiazemThe metabolism of Paclitaxel can be decreased when combined with Diltiazem.
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Paclitaxel.
DinutuximabThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Dinutuximab.
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Paclitaxel.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Paclitaxel.
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Paclitaxel.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Paclitaxel.
DoxazosinThe serum concentration of Paclitaxel can be increased when it is combined with Doxazosin.
DoxepinThe serum concentration of Paclitaxel can be increased when it is combined with Doxepin.
DoxorubicinThe serum concentration of Paclitaxel can be decreased when it is combined with Doxorubicin.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Paclitaxel.
DoxycyclineThe metabolism of Paclitaxel can be decreased when combined with Doxycycline.
DronabinolThe serum concentration of Paclitaxel can be increased when it is combined with Dronabinol.
DronedaroneThe metabolism of Paclitaxel can be decreased when combined with Dronedarone.
EcabetThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Ecabet.
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Paclitaxel.
efaproxiralThe risk or severity of adverse effects can be increased when Paclitaxel is combined with efaproxiral.
EfavirenzThe serum concentration of Paclitaxel can be decreased when it is combined with Efavirenz.
EflornithineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Eflornithine.
EG009The risk or severity of adverse effects can be increased when Paclitaxel is combined with EG009.
ElbasvirThe serum concentration of Paclitaxel can be increased when it is combined with Elbasvir.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Paclitaxel.
ElsamitrucinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Elsamitrucin.
EltrombopagThe serum concentration of Paclitaxel can be increased when it is combined with Eltrombopag.
EnalaprilThe serum concentration of Paclitaxel can be increased when it is combined with Enalapril.
EndostatinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Endostatin.
EnoxacinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Enoxacin.
EnrofloxacinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Enrofloxacin.
EnzalutamideThe serum concentration of Paclitaxel can be increased when it is combined with Enzalutamide.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Paclitaxel.
EpirubicinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Epirubicin.
Epothilone BThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Epothilone B.
ErgonovineThe serum concentration of Paclitaxel can be increased when it is combined with Ergonovine.
ErgotamineThe serum concentration of Paclitaxel can be increased when it is combined with Ergotamine.
EribulinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Eribulin.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Paclitaxel.
ErythromycinThe metabolism of Paclitaxel can be decreased when combined with Erythromycin.
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Paclitaxel.
Eslicarbazepine acetateThe serum concentration of Paclitaxel can be decreased when it is combined with Eslicarbazepine acetate.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Paclitaxel.
EstramustineThe serum concentration of Paclitaxel can be increased when it is combined with Estramustine.
EstramustineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Estramustine.
EstriolThe serum concentration of Paclitaxel can be decreased when it is combined with Estriol.
EstriolThe serum concentration of Estriol can be increased when it is combined with Paclitaxel.
EstroneThe serum concentration of Paclitaxel can be decreased when it is combined with Estrone.
EstroneThe serum concentration of Estrone can be increased when it is combined with Paclitaxel.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Paclitaxel.
Ethiodized oilThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Ethiodized oil.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Ethyl carbamate.
EtoposideThe serum concentration of Paclitaxel can be increased when it is combined with Etoposide.
EtravirineThe serum concentration of Paclitaxel can be decreased when it is combined with Etravirine.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Paclitaxel.
ExemestaneThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Exemestane.
exisulindThe risk or severity of adverse effects can be increased when Paclitaxel is combined with exisulind.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Paclitaxel.
FelodipineThe serum concentration of Paclitaxel can be increased when it is combined with Felodipine.
FenretinideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Fenretinide.
FentanylThe serum concentration of Paclitaxel can be increased when it is combined with Fentanyl.
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Paclitaxel.
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Paclitaxel.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Paclitaxel.
FingolimodPaclitaxel may increase the immunosuppressive activities of Fingolimod.
FlavopiridolThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Flavopiridol.
FleroxacinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Fleroxacin.
FloxuridineThe metabolism of Paclitaxel can be decreased when combined with Floxuridine.
FloxuridineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Floxuridine.
FluconazoleThe metabolism of Paclitaxel can be decreased when combined with Fluconazole.
FludarabineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Fludarabine.
FlumequineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Flumequine.
FluorouracilThe metabolism of Paclitaxel can be decreased when combined with Fluorouracil.
FluorouracilThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Fluorouracil.
FluoxetineThe serum concentration of Paclitaxel can be increased when it is combined with Fluoxetine.
FlupentixolThe serum concentration of Paclitaxel can be increased when it is combined with Flupentixol.
FluphenazineThe serum concentration of Paclitaxel can be increased when it is combined with Fluphenazine.
FlurazepamThe serum concentration of Paclitaxel can be increased when it is combined with Flurazepam.
FlutamideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Flutamide.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Paclitaxel.
FluvastatinThe metabolism of Paclitaxel can be decreased when combined with Fluvastatin.
FluvoxamineThe metabolism of Paclitaxel can be decreased when combined with Fluvoxamine.
FormestaneThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Formestane.
FormycinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Formycin.
FosamprenavirThe metabolism of Paclitaxel can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Paclitaxel can be increased when it is combined with Fosaprepitant.
FosphenytoinThe metabolism of Paclitaxel can be increased when combined with Fosphenytoin.
FotemustineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Fotemustine.
FulvestrantThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Fulvestrant.
FumagillinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Fumagillin.
Fusidic AcidThe serum concentration of Paclitaxel can be increased when it is combined with Fusidic Acid.
Gallium nitrateThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Gallium nitrate.
GarenoxacinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Garenoxacin.
GatifloxacinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Gatifloxacin.
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Paclitaxel.
GeldanamycinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Geldanamycin.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Paclitaxel.
GemfibrozilThe metabolism of Paclitaxel can be decreased when combined with Gemfibrozil.
GemifloxacinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Gemifloxacin.
Gemtuzumab ozogamicinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Gemtuzumab ozogamicin.
GenisteinThe serum concentration of Paclitaxel can be increased when it is combined with Genistein.
GenisteinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Genistein.
Ginsenoside CThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Ginsenoside C.
GlyburideThe serum concentration of Paclitaxel can be increased when it is combined with Glyburide.
GlycerolThe serum concentration of Paclitaxel can be increased when it is combined with Glycerol.
GoserelinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Goserelin.
Gramicidin DThe serum concentration of Paclitaxel can be increased when it is combined with Gramicidin D.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Paclitaxel.
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Paclitaxel.
HadacidinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Hadacidin.
HalofuginoneThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Halofuginone.
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Paclitaxel.
HexestrolThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Hexestrol.
HydrocodoneThe serum concentration of Hydrocodone can be decreased when it is combined with Paclitaxel.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Paclitaxel.
Hydroxyprogesterone caproateThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Hydroxyprogesterone caproate.
HydroxyureaThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Hydroxyurea.
IbrutinibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Ibrutinib.
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Paclitaxel.
IdarubicinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Idarubicin.
IdelalisibThe serum concentration of Paclitaxel can be increased when it is combined with Idelalisib.
IfosfamideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Ifosfamide.
ImatinibThe metabolism of Paclitaxel can be decreased when combined with Imatinib.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Paclitaxel.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Paclitaxel.
ImiquimodThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Imiquimod.
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Paclitaxel.
IndinavirThe serum concentration of Paclitaxel can be decreased when it is combined with Indinavir.
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Paclitaxel.
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Paclitaxel.
Interferon beta-1aThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Interferon beta-1a.
IobenguaneThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Iobenguane.
IpilimumabThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Ipilimumab.
IrbesartanThe metabolism of Paclitaxel can be decreased when combined with Irbesartan.
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Paclitaxel.
IsavuconazoniumThe metabolism of Paclitaxel can be decreased when combined with Isavuconazonium.
IsradipineThe metabolism of Paclitaxel can be decreased when combined with Isradipine.
ItraconazoleThe serum concentration of Paclitaxel can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Paclitaxel can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Paclitaxel.
IxabepiloneThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Ixabepilone.
IxazomibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Ixazomib.
KetamineThe serum concentration of Paclitaxel can be increased when it is combined with Ketamine.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Paclitaxel.
KetoconazoleThe serum concentration of Paclitaxel can be increased when it is combined with Ketoconazole.
KOS-1584The risk or severity of adverse effects can be increased when Paclitaxel is combined with KOS-1584.
L-alanosineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with L-alanosine.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Paclitaxel.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Paclitaxel.
LanreotideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Lanreotide.
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Paclitaxel.
LapatinibThe serum concentration of Paclitaxel can be increased when it is combined with Lapatinib.
LapatinibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Lapatinib.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Paclitaxel.
LeflunomideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Leflunomide.
LeflunomideThe metabolism of Paclitaxel can be decreased when combined with Leflunomide.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Paclitaxel.
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Paclitaxel.
LetrozoleThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Letrozole.
LeuprolideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Leuprolide.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Paclitaxel.
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Paclitaxel.
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Paclitaxel.
LevothyroxineThe serum concentration of Paclitaxel can be decreased when it is combined with Levothyroxine.
LidocaineThe serum concentration of Paclitaxel can be increased when it is combined with Lidocaine.
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Paclitaxel.
LiothyronineThe serum concentration of Paclitaxel can be decreased when it is combined with Liothyronine.
LiotrixThe serum concentration of Paclitaxel can be decreased when it is combined with Liotrix.
LisinoprilThe serum concentration of Paclitaxel can be increased when it is combined with Lisinopril.
LomefloxacinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Lomefloxacin.
LomitapideThe serum concentration of Paclitaxel can be increased when it is combined with Lomitapide.
LomustineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Lomustine.
LonidamineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Lonidamine.
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Paclitaxel.
LopinavirThe serum concentration of Paclitaxel can be increased when it is combined with Lopinavir.
LoratadineThe serum concentration of Paclitaxel can be increased when it is combined with Loratadine.
LosartanThe serum concentration of Losartan can be increased when it is combined with Paclitaxel.
LovastatinThe metabolism of Paclitaxel can be decreased when combined with Lovastatin.
LuliconazoleThe serum concentration of Paclitaxel can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Paclitaxel can be decreased when it is combined with Lumacaftor.
LycopeneThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Lycopene.
MannitolThe serum concentration of Mannitol can be increased when it is combined with Paclitaxel.
MaprotilineThe serum concentration of Paclitaxel can be increased when it is combined with Maprotiline.
MasitinibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Masitinib.
MasoprocolThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Masoprocol.
MaxacalcitolThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Maxacalcitol.
MDX-1106The risk or severity of adverse effects can be increased when Paclitaxel is combined with MDX-1106.
MebendazoleThe serum concentration of Paclitaxel can be increased when it is combined with Mebendazole.
MebendazoleThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Mebendazole.
MechlorethamineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Mechlorethamine.
MedrogestoneThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Medrogestone.
Medroxyprogesterone acetateThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Medroxyprogesterone acetate.
MefloquineThe serum concentration of Paclitaxel can be increased when it is combined with Mefloquine.
Megestrol acetateThe serum concentration of Paclitaxel can be increased when it is combined with Megestrol acetate.
Megestrol acetateThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Megestrol acetate.
MelphalanThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Melphalan.
MeprobamateThe serum concentration of Paclitaxel can be increased when it is combined with Meprobamate.
MequinolThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Mequinol.
MercaptopurineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Mercaptopurine.
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Paclitaxel.
MethadoneThe serum concentration of Paclitaxel can be increased when it is combined with Methadone.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Paclitaxel.
Methyl aminolevulinateThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Methyl aminolevulinate.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Paclitaxel.
MethyltestosteroneThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Methyltestosterone.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Paclitaxel.
MGI-114The risk or severity of adverse effects can be increased when Paclitaxel is combined with MGI-114.
MibefradilThe serum concentration of Paclitaxel can be increased when it is combined with Mibefradil.
MiconazoleThe serum concentration of Paclitaxel can be increased when it is combined with Miconazole.
MidazolamThe serum concentration of Paclitaxel can be decreased when it is combined with Midazolam.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Paclitaxel.
MidostaurinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Midostaurin.
MifepristoneThe metabolism of Paclitaxel can be decreased when combined with Mifepristone.
MiltefosineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Miltefosine.
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Paclitaxel.
MitomycinThe serum concentration of Paclitaxel can be increased when it is combined with Mitomycin.
MitomycinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Mitomycin.
MitotaneThe serum concentration of Paclitaxel can be decreased when it is combined with Mitotane.
MitotaneThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Mitotane.
MitoxantroneThe serum concentration of Paclitaxel can be decreased when it is combined with Mitoxantrone.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Paclitaxel.
ModafinilThe serum concentration of Paclitaxel can be decreased when it is combined with Modafinil.
MorphineThe serum concentration of Morphine can be increased when it is combined with Paclitaxel.
motexafin gadoliniumThe risk or severity of adverse effects can be increased when Paclitaxel is combined with motexafin gadolinium.
MoxifloxacinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Moxifloxacin.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Paclitaxel.
Mycophenolic acidThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Mycophenolic acid.
NadololThe serum concentration of Nadolol can be increased when it is combined with Paclitaxel.
NafcillinThe serum concentration of Paclitaxel can be decreased when it is combined with Nafcillin.
Nalidixic AcidThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Nalidixic Acid.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Paclitaxel.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Paclitaxel.
NaltrexoneThe serum concentration of Paclitaxel can be increased when it is combined with Naltrexone.
NaringeninThe serum concentration of Paclitaxel can be increased when it is combined with Naringenin.
NatalizumabThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Natalizumab.
NecitumumabThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Necitumumab.
NefazodoneThe serum concentration of Paclitaxel can be decreased when it is combined with Nefazodone.
NelarabineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Nelarabine.
NelfinavirThe serum concentration of Paclitaxel can be decreased when it is combined with Nelfinavir.
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Paclitaxel.
NeostigmineThe serum concentration of Paclitaxel can be increased when it is combined with Neostigmine.
NetupitantThe serum concentration of Paclitaxel can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Paclitaxel can be decreased when combined with Nevirapine.
NicardipineThe serum concentration of Paclitaxel can be increased when it is combined with Nicardipine.
NifedipineThe serum concentration of Paclitaxel can be decreased when it is combined with Nifedipine.
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Paclitaxel.
NiguldipineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Niguldipine.
NilotinibThe metabolism of Paclitaxel can be decreased when combined with Nilotinib.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Paclitaxel.
NilutamideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Nilutamide.
NimodipineThe serum concentration of Nimodipine can be decreased when it is combined with Paclitaxel.
NintedanibThe serum concentration of Nintedanib can be decreased when it is combined with Paclitaxel.
NisoldipineThe serum concentration of Paclitaxel can be increased when it is combined with Nisoldipine.
NitrazepamThe serum concentration of Paclitaxel can be increased when it is combined with Nitrazepam.
NitrendipineThe serum concentration of Paclitaxel can be increased when it is combined with Nitrendipine.
NivolumabThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Nivolumab.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Paclitaxel.
nocodazoleThe risk or severity of adverse effects can be increased when Paclitaxel is combined with nocodazole.
NorethisteroneThe serum concentration of Paclitaxel can be decreased when it is combined with Norethisterone.
NorfloxacinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Norfloxacin.
ObinutuzumabThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Obinutuzumab.
OctreotideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Octreotide.
OfatumumabThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Ofatumumab.
OfloxacinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Ofloxacin.
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Paclitaxel.
OlaparibThe metabolism of Paclitaxel can be decreased when combined with Olaparib.
OlaparibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Olaparib.
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Omacetaxine mepesuccinate.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Paclitaxel.
OmeprazoleThe serum concentration of Paclitaxel can be increased when it is combined with Omeprazole.
OprelvekinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Oprelvekin.
OsimertinibThe serum concentration of Paclitaxel can be increased when it is combined with Osimertinib.
OuabainOuabain may decrease the cardiotoxic activities of Paclitaxel.
OxaliplatinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Oxaliplatin.
P-NitrophenolThe serum concentration of Paclitaxel can be increased when it is combined with P-Nitrophenol.
PalbociclibThe serum concentration of Paclitaxel can be increased when it is combined with Palbociclib.
PalbociclibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Palbociclib.
PalifosfamideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Palifosfamide.
Palmitic AcidThe serum concentration of Paclitaxel can be increased when it is combined with Palmitic Acid.
PamidronateThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Pamidronate.
PanitumumabThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Panitumumab.
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Paclitaxel.
PantoprazoleThe serum concentration of Paclitaxel can be increased when it is combined with Pantoprazole.
ParoxetineThe serum concentration of Paclitaxel can be increased when it is combined with Paroxetine.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Paclitaxel.
PefloxacinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Pefloxacin.
PegaspargaseThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Pegaspargase.
PembrolizumabThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Pembrolizumab.
PemetrexedThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Pemetrexed.
PentobarbitalThe metabolism of Paclitaxel can be increased when combined with Pentobarbital.
PentostatinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Pentostatin.
PerindoprilThe serum concentration of Paclitaxel can be increased when it is combined with Perindopril.
PertuzumabThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Pertuzumab.
PhenobarbitalThe serum concentration of Paclitaxel can be decreased when it is combined with Phenobarbital.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Paclitaxel.
Phenylacetic acidThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Phenylacetic acid.
PhenytoinThe metabolism of Paclitaxel can be increased when combined with Phenytoin.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Paclitaxel.
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Paclitaxel.
PimozideThe serum concentration of Paclitaxel can be increased when it is combined with Pimozide.
PioglitazoneThe metabolism of Paclitaxel can be decreased when combined with Pioglitazone.
PipobromanThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Pipobroman.
PirfenidoneThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Pirfenidone.
PirlindoleThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Pirlindole.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Paclitaxel.
PixantroneThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Pixantrone.
Platelet Activating FactorThe serum concentration of Paclitaxel can be decreased when it is combined with Platelet Activating Factor.
PlicamycinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Plicamycin.
PodofiloxThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Podofilox.
PodophyllinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Podophyllin.
polyacrylic acidThe risk or severity of adverse effects can be increased when Paclitaxel is combined with polyacrylic acid.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Paclitaxel.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Paclitaxel.
PorfimerThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Porfimer.
porfiromycinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with porfiromycin.
PosaconazoleThe serum concentration of Paclitaxel can be increased when it is combined with Posaconazole.
PralatrexateThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Pralatrexate.
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Paclitaxel.
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Paclitaxel.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Paclitaxel.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Paclitaxel.
PrimidoneThe metabolism of Paclitaxel can be increased when combined with Primidone.
ProbenecidThe serum concentration of Paclitaxel can be increased when it is combined with Probenecid.
ProcarbazineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Procarbazine.
ProgesteroneThe serum concentration of Paclitaxel can be decreased when it is combined with Progesterone.
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Paclitaxel.
PromethazineThe serum concentration of Paclitaxel can be increased when it is combined with Promethazine.
PropafenoneThe serum concentration of Paclitaxel can be increased when it is combined with Propafenone.
PropranololThe serum concentration of Propranolol can be increased when it is combined with Paclitaxel.
ProtriptylineThe serum concentration of Paclitaxel can be increased when it is combined with Protriptyline.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Paclitaxel.
Purine RibosideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Purine Riboside.
PuromycinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Puromycin.
PyrimethamineThe metabolism of Paclitaxel can be decreased when combined with Pyrimethamine.
QuercetinThe serum concentration of Paclitaxel can be increased when it is combined with Quercetin.
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Paclitaxel.
QuinacrineThe serum concentration of Paclitaxel can be increased when it is combined with Quinacrine.
QuinacrineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Quinacrine.
QuinidineThe serum concentration of Paclitaxel can be increased when it is combined with Quinidine.
QuinineThe serum concentration of Quinine can be increased when it is combined with Paclitaxel.
RabeprazoleThe metabolism of Paclitaxel can be decreased when combined with Rabeprazole.
Rabies vaccineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Rabies vaccine.
Radium Ra 223 DichlorideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Radium Ra 223 Dichloride.
RaltitrexedThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Raltitrexed.
RamucirumabThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Ramucirumab.
RanibizumabThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Ranibizumab.
RanitidineThe serum concentration of Paclitaxel can be increased when it is combined with Ranitidine.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Paclitaxel.
RanpirnaseThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Ranpirnase.
ReboxetineThe serum concentration of Paclitaxel can be increased when it is combined with Reboxetine.
RegorafenibThe serum concentration of Paclitaxel can be increased when it is combined with Regorafenib.
RegorafenibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Regorafenib.
ReserpineThe serum concentration of Paclitaxel can be decreased when it is combined with Reserpine.
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Paclitaxel.
ResveratrolThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Resveratrol.
Rhodamine 6GThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Rhodamine 6G.
RifabutinThe metabolism of Paclitaxel can be increased when combined with Rifabutin.
RifampicinThe serum concentration of Paclitaxel can be decreased when it is combined with Rifampicin.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Paclitaxel.
RifapentineThe metabolism of Paclitaxel can be increased when combined with Rifapentine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Paclitaxel.
RilpivirineThe serum concentration of Paclitaxel can be increased when it is combined with Rilpivirine.
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Paclitaxel.
RitonavirThe serum concentration of Paclitaxel can be decreased when it is combined with Ritonavir.
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Paclitaxel.
RituximabThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Rituximab.
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Paclitaxel.
RoflumilastRoflumilast may increase the immunosuppressive activities of Paclitaxel.
RolapitantThe serum concentration of Paclitaxel can be increased when it is combined with Rolapitant.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Paclitaxel.
RomiplostimThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Romiplostim.
RoquinimexThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Roquinimex.
RosiglitazoneThe metabolism of Paclitaxel can be decreased when combined with Rosiglitazone.
RubitecanThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Rubitecan.
RuxolitinibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Ruxolitinib.
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Paclitaxel.
SaquinavirThe serum concentration of Paclitaxel can be decreased when it is combined with Saquinavir.
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Paclitaxel.
SatraplatinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Satraplatin.
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Paclitaxel.
ScopolamineThe serum concentration of Paclitaxel can be increased when it is combined with Scopolamine.
SecobarbitalThe metabolism of Paclitaxel can be increased when combined with Secobarbital.
SelegilineThe serum concentration of Paclitaxel can be increased when it is combined with Selegiline.
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Paclitaxel.
SeliciclibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Seliciclib.
SemaxanibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Semaxanib.
SeocalcitolThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Seocalcitol.
SertralineThe serum concentration of Paclitaxel can be increased when it is combined with Sertraline.
SildenafilThe metabolism of Paclitaxel can be decreased when combined with Sildenafil.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Paclitaxel.
SiltuximabThe serum concentration of Paclitaxel can be decreased when it is combined with Siltuximab.
SiltuximabThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Siltuximab.
SimeprevirThe serum concentration of Paclitaxel can be increased when it is combined with Simeprevir.
SimvastatinThe serum concentration of Paclitaxel can be increased when it is combined with Simvastatin.
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Paclitaxel.
SirolimusThe serum concentration of Paclitaxel can be decreased when it is combined with Sirolimus.
SirolimusThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Sirolimus.
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Paclitaxel.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Paclitaxel.
SonidegibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Sonidegib.
SorafenibThe risk or severity of adverse effects can be increased when Sorafenib is combined with Paclitaxel.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Paclitaxel.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Paclitaxel.
Sparfosic acidThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Sparfosic acid.
SparsomycinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Sparsomycin.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Paclitaxel.
SpironolactoneThe serum concentration of Paclitaxel can be increased when it is combined with Spironolactone.
squalamineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with squalamine.
SRT501The risk or severity of adverse effects can be increased when Paclitaxel is combined with SRT501.
St. John's WortThe serum concentration of Paclitaxel can be decreased when it is combined with St. John's Wort.
StaurosporineThe serum concentration of Paclitaxel can be increased when it is combined with Staurosporine.
StiripentolThe serum concentration of Paclitaxel can be increased when it is combined with Stiripentol.
StreptozocinThe serum concentration of Paclitaxel can be decreased when it is combined with Streptozocin.
StreptozocinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Streptozocin.
SulfadiazineThe metabolism of Paclitaxel can be decreased when combined with Sulfadiazine.
SulfamethoxazoleThe metabolism of Paclitaxel can be decreased when combined with Sulfamethoxazole.
SulfinpyrazoneThe serum concentration of Paclitaxel can be increased when it is combined with Sulfinpyrazone.
SulfisoxazoleThe metabolism of Paclitaxel can be decreased when combined with Sulfisoxazole.
SulindacThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Sulindac.
SumatriptanThe serum concentration of Paclitaxel can be increased when it is combined with Sumatriptan.
SunitinibThe serum concentration of Paclitaxel can be increased when it is combined with Sunitinib.
SunitinibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Sunitinib.
SuraminThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Suramin.
SwainsonineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Swainsonine.
TacrineThe serum concentration of Paclitaxel can be increased when it is combined with Tacrine.
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Paclitaxel.
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Paclitaxel.
TamoxifenThe serum concentration of Paclitaxel can be decreased when it is combined with Tamoxifen.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Paclitaxel.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Paclitaxel.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Paclitaxel.
TegafurThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Tegafur.
TelaprevirThe metabolism of Paclitaxel can be decreased when combined with Telaprevir.
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Paclitaxel.
TelithromycinThe metabolism of Paclitaxel can be decreased when combined with Telithromycin.
TelmisartanThe serum concentration of Paclitaxel can be increased when it is combined with Telmisartan.
TemafloxacinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Temafloxacin.
TemozolomideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Temozolomide.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Paclitaxel.
TeniposideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Teniposide.
TerazosinThe serum concentration of Paclitaxel can be increased when it is combined with Terazosin.
TerfenadineThe serum concentration of Paclitaxel can be increased when it is combined with Terfenadine.
TeriflunomideThe serum concentration of Paclitaxel can be increased when it is combined with Teriflunomide.
TesmilifeneThe serum concentration of Paclitaxel can be decreased when it is combined with Tesmilifene.
TestolactoneThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Testolactone.
TestosteroneThe serum concentration of Paclitaxel can be increased when it is combined with Testosterone.
TetrathiomolybdateThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Tetrathiomolybdate.
TezacitabineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Tezacitabine.
ThalidomideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Thalidomide.
ThiotepaThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Thiotepa.
ThymalfasinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Thymalfasin.
TiboloneThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Tibolone.
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Paclitaxel.
TiclopidineThe metabolism of Paclitaxel can be decreased when combined with Ticlopidine.
TimololThe serum concentration of Timolol can be increased when it is combined with Paclitaxel.
TioguanineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Tioguanine.
TipifarnibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Tipifarnib.
TirapazamineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Tirapazamine.
TocilizumabThe serum concentration of Paclitaxel can be decreased when it is combined with Tocilizumab.
TofacitinibPaclitaxel may increase the immunosuppressive activities of Tofacitinib.
TolbutamideThe metabolism of Paclitaxel can be decreased when combined with Tolbutamide.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Paclitaxel.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Paclitaxel.
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Paclitaxel.
TositumomabThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Tositumomab.
TrabectedinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Trabectedin.
TrametinibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Trametinib.
TrastuzumabThe serum concentration of Paclitaxel can be decreased when it is combined with Trastuzumab.
TrastuzumabThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Trastuzumab.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Paclitaxel.
TrazodoneThe serum concentration of Paclitaxel can be decreased when it is combined with Trazodone.
TretinoinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Tretinoin.
TrifluoperazineThe serum concentration of Paclitaxel can be increased when it is combined with Trifluoperazine.
TriflupromazineThe serum concentration of Paclitaxel can be increased when it is combined with Triflupromazine.
TrifluridineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Trifluridine.
TrilostaneThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Trilostane.
TrimethoprimThe serum concentration of Paclitaxel can be decreased when it is combined with Trimethoprim.
TrimetrexateThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Trimetrexate.
TrimipramineThe serum concentration of Paclitaxel can be increased when it is combined with Trimipramine.
TriptorelinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Triptorelin.
TroleandomycinThe serum concentration of Paclitaxel can be increased when it is combined with Troleandomycin.
TrovafloxacinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Trovafloxacin.
TroxacitabineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Troxacitabine.
TTNPBThe risk or severity of adverse effects can be increased when Paclitaxel is combined with TTNPB.
TubercidinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Tubercidin.
UbenimexThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Ubenimex.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Paclitaxel.
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Paclitaxel.
Uracil mustardThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Uracil mustard.
Valproic AcidThe metabolism of Paclitaxel can be decreased when combined with Valproic Acid.
ValrubicinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Valrubicin.
ValsartanThe metabolism of Paclitaxel can be decreased when combined with Valsartan.
VandetanibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Vandetanib.
VapreotideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Vapreotide.
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Paclitaxel.
VeliparibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Veliparib.
VemurafenibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Vemurafenib.
VenlafaxineThe metabolism of Paclitaxel can be decreased when combined with Venlafaxine.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Paclitaxel.
VerapamilThe metabolism of Paclitaxel can be decreased when combined with Verapamil.
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Paclitaxel.
VerteporfinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Verteporfin.
VinblastineThe serum concentration of Paclitaxel can be decreased when it is combined with Vinblastine.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Paclitaxel.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Paclitaxel.
VincristineThe serum concentration of Paclitaxel can be decreased when it is combined with Vincristine.
VindesineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Vindesine.
VinorelbinePaclitaxel may increase the neurotoxic activities of Vinorelbine.
VinorelbineThe serum concentration of Paclitaxel can be increased when it is combined with Vinorelbine.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Paclitaxel.
Vitamin AThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Vitamin A.
VoriconazoleThe metabolism of Paclitaxel can be decreased when combined with Voriconazole.
VorinostatThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Vorinostat.
ZafirlukastThe metabolism of Paclitaxel can be decreased when combined with Zafirlukast.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Paclitaxel.
ZimelidineThe serum concentration of Paclitaxel can be increased when it is combined with Zimelidine.
ZiprasidoneThe metabolism of Paclitaxel can be decreased when combined with Ziprasidone.
Food Interactions
  • Avoid echinacea.
  • Avoid grapefruit and grapefruit juice due to potential increase of paclitaxel.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Ubiquitin protein ligase binding
Specific Function:
Suppresses apoptosis in a variety of cell systems including factor-dependent lymphohematopoietic and neural cells. Regulates cell death by controlling the mitochondrial membrane permeability. Appears to function in a feedback loop system with caspases. Inhibits caspase activity either by preventing the release of cytochrome c from the mitochondria and/or by binding to the apoptosis-activating f...
Gene Name:
BCL2
Uniprot ID:
P10415
Molecular Weight:
26265.66 Da
References
  1. Gan Y, Wientjes MG, Au JL: Expression of basic fibroblast growth factor correlates with resistance to paclitaxel in human patient tumors. Pharm Res. 2006 Jun;23(6):1324-31. Epub 2006 Jun 8. [PubMed:16741658 ]
  2. Thomadaki H, Talieri M, Scorilas A: Treatment of MCF-7 cells with taxol and etoposide induces distinct alterations in the expression of apoptosis-related genes BCL2, BCL2L12, BAX, CASPASE-9 and FAS. Biol Chem. 2006 Aug;387(8):1081-6. [PubMed:16895478 ]
  3. Yoshino T, Shiina H, Urakami S, Kikuno N, Yoneda T, Shigeno K, Igawa M: Bcl-2 expression as a predictive marker of hormone-refractory prostate cancer treated with taxane-based chemotherapy. Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6116-24. [PubMed:17062688 ]
  4. Matsuyoshi S, Shimada K, Nakamura M, Ishida E, Konishi N: Bcl-2 phosphorylation has pathological significance in human breast cancer. Pathobiology. 2006;73(4):205-12. [PubMed:17119350 ]
  5. Zhang X, Wang Q, Ling MT, Wong YC, Leung SC, Wang X: Anti-apoptotic role of TWIST and its association with Akt pathway in mediating taxol resistance in nasopharyngeal carcinoma cells. Int J Cancer. 2007 May 1;120(9):1891-8. [PubMed:17230521 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Structural constituent of cytoskeleton
Specific Function:
Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain (By similarity).
Gene Name:
TUBB1
Uniprot ID:
Q9H4B7
Molecular Weight:
50326.56 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Cheung CH, Chen HH, Kuo CC, Chang CY, Coumar MS, Hsieh HP, Chang JY: Survivin counteracts the therapeutic effect of microtubule de-stabilizers by stabilizing tubulin polymers. Mol Cancer. 2009 Jul 3;8:43. doi: 10.1186/1476-4598-8-43. [PubMed:19575780 ]
  4. Horwitz SB: Mechanism of action of taxol. Trends Pharmacol Sci. 1992 Apr;13(4):134-6. [PubMed:1350385 ]
  5. Kovacs P, Csaba G, Pallinger E, Czaker R: Effects of taxol treatment on the microtubular system and mitochondria of Tetrahymena. Cell Biol Int. 2007 Jul;31(7):724-32. Epub 2007 Jan 14. [PubMed:17314054 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Zinc ion binding
Specific Function:
Nuclear receptor that binds and is activated by variety of endogenous and xenobiotic compounds. Transcription factor that activates the transcription of multiple genes involved in the metabolism and secretion of potentially harmful xenobiotics, drugs and endogenous compounds. Activated by the antibiotic rifampicin and various plant metabolites, such as hyperforin, guggulipid, colupulone, and is...
Gene Name:
NR1I2
Uniprot ID:
O75469
Molecular Weight:
49761.245 Da
References
  1. Harmsen S, Meijerman I, Beijnen JH, Schellens JH: Nuclear receptor mediated induction of cytochrome P450 3A4 by anticancer drugs: a key role for the pregnane X receptor. Cancer Chemother Pharmacol. 2009 Jun;64(1):35-43. doi: 10.1007/s00280-008-0842-3. Epub 2008 Oct 7. [PubMed:18839173 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
General Function:
Structural molecule activity
Specific Function:
Non-neuronal microtubule-associated protein. Promotes microtubule assembly.
Gene Name:
MAP4
Uniprot ID:
P27816
Molecular Weight:
121003.805 Da
References
  1. McGrogan BT, Gilmartin B, Carney DN, McCann A: Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta. 2008 Apr;1785(2):96-132. Epub 2007 Nov 12. [PubMed:18068131 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
General Function:
Structural molecule activity
Specific Function:
The exact function of MAP2 is unknown but MAPs may stabilize the microtubules against depolymerization. They also seem to have a stiffening effect on microtubules.
Gene Name:
MAP2
Uniprot ID:
P11137
Molecular Weight:
199524.51 Da
References
  1. McGrogan BT, Gilmartin B, Carney DN, McCann A: Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta. 2008 Apr;1785(2):96-132. Epub 2007 Nov 12. [PubMed:18068131 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
General Function:
Structural constituent of cytoskeleton
Specific Function:
Promotes microtubule assembly and stability, and might be involved in the establishment and maintenance of neuronal polarity. The C-terminus binds axonal microtubules while the N-terminus binds neural plasma membrane components, suggesting that tau functions as a linker protein between both. Axonal polarity is predetermined by TAU/MAPT localization (in the neuronal cell) in the domain of the ce...
Gene Name:
MAPT
Uniprot ID:
P10636
Molecular Weight:
78927.025 Da
References
  1. McGrogan BT, Gilmartin B, Carney DN, McCann A: Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta. 2008 Apr;1785(2):96-132. Epub 2007 Nov 12. [PubMed:18068131 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Yu L, Shi D, Ma L, Zhou Q, Zeng S: Influence of CYP2C8 polymorphisms on the hydroxylation metabolism of paclitaxel, repaglinide and ibuprofen enantiomers in vitro. Biopharm Drug Dispos. 2013 Jul;34(5):278-87. doi: 10.1002/bdd.1842. Epub 2013 Jun 3. [PubMed:23536207 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxygen binding
Specific Function:
Catalyzes the formation of aromatic C18 estrogens from C19 androgens.
Gene Name:
CYP19A1
Uniprot ID:
P11511
Molecular Weight:
57882.48 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, retinoid and xenobiotics. Preferentially oxidizes 17beta-estradiol to the carcinogenic 4-hydroxy derivative, and a variety of procarcinogenic compou...
Gene Name:
CYP1B1
Uniprot ID:
Q16678
Molecular Weight:
60845.33 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Transporter activity
Specific Function:
Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.
Gene Name:
ABCB11
Uniprot ID:
O95342
Molecular Weight:
146405.83 Da
References
  1. Wang EJ, Casciano CN, Clement RP, Johnson WW: Fluorescent substrates of sister-P-glycoprotein (BSEP) evaluated as markers of active transport and inhibition: evidence for contingent unequal binding sites. Pharm Res. 2003 Apr;20(4):537-44. [PubMed:12739759 ]
  2. Lecureur V, Sun D, Hargrove P, Schuetz EG, Kim RB, Lan LB, Schuetz JD: Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/P-glycoprotein. Mol Pharmacol. 2000 Jan;57(1):24-35. [PubMed:10617675 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther. 2001 Nov;299(2):620-8. [PubMed:11602674 ]
  2. Wang EJ, Casciano CN, Clement RP, Johnson WW: Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. Biochem Biophys Res Commun. 2001 Nov 30;289(2):580-5. [PubMed:11716514 ]
  3. Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9. [PubMed:14985103 ]
  4. Jang SH, Wientjes MG, Au JL: Kinetics of P-glycoprotein-mediated efflux of paclitaxel. J Pharmacol Exp Ther. 2001 Sep;298(3):1236-42. [PubMed:11504826 ]
  5. Li D, Jang SH, Kim J, Wientjes MG, Au JL: Enhanced drug-induced apoptosis associated with P-glycoprotein overexpression is specific to antimicrotubule agents. Pharm Res. 2003 Jan;20(1):45-50. [PubMed:12608535 ]
  6. Troutman MD, Thakker DR: Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm Res. 2003 Aug;20(8):1210-24. [PubMed:12948019 ]
  7. Kim S, Kim SS, Bang YJ, Kim SJ, Lee BJ: In vitro activities of native and designed peptide antibiotics against drug sensitive and resistant tumor cell lines. Peptides. 2003 Jul;24(7):945-53. [PubMed:14499271 ]
  8. Walle UK, Walle T: Taxol transport by human intestinal epithelial Caco-2 cells. Drug Metab Dispos. 1998 Apr;26(4):343-6. [PubMed:9531522 ]
  9. Lecureur V, Sun D, Hargrove P, Schuetz EG, Kim RB, Lan LB, Schuetz JD: Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/P-glycoprotein. Mol Pharmacol. 2000 Jan;57(1):24-35. [PubMed:10617675 ]
  10. Collett A, Tanianis-Hughes J, Hallifax D, Warhurst G: Predicting P-glycoprotein effects on oral absorption: correlation of transport in Caco-2 with drug pharmacokinetics in wild-type and mdr1a(-/-) mice in vivo. Pharm Res. 2004 May;21(5):819-26. [PubMed:15180340 ]
  11. Kuo CC, Hsieh HP, Pan WY, Chen CP, Liou JP, Lee SJ, Chang YL, Chen LT, Chen CT, Chang JY: BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo. Cancer Res. 2004 Jul 1;64(13):4621-8. [PubMed:15231674 ]
  12. Li YC, Fung KP, Kwok TT, Lee CY, Suen YK, Kong SK: Mitochondria-targeting drug oligomycin blocked P-glycoprotein activity and triggered apoptosis in doxorubicin-resistant HepG2 cells. Chemotherapy. 2004 Jun;50(2):55-62. [PubMed:15211078 ]
  13. Kwak JO, Lee SH, Lee GS, Kim MS, Ahn YG, Lee JH, Kim SW, Kim KH, Lee MG: Selective inhibition of MDR1 (ABCB1) by HM30181 increases oral bioavailability and therapeutic efficacy of paclitaxel. Eur J Pharmacol. 2010 Feb 10;627(1-3):92-8. doi: 10.1016/j.ejphar.2009.11.008. Epub 2009 Nov 10. [PubMed:19903471 ]
  14. Woodahl EL, Crouthamel MH, Bui T, Shen DD, Ho RJ: MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8. doi: 10.1007/s00280-008-0906-4. Epub 2009 Jan 4. [PubMed:19123050 ]
  15. Tiwari AK, Sodani K, Wang SR, Kuang YH, Ashby CR Jr, Chen X, Chen ZS: Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. Biochem Pharmacol. 2009 Jul 15;78(2):153-61. doi: 10.1016/j.bcp.2009.04.002. Epub 2009 Apr 11. [PubMed:19427995 ]
  16. Noguchi K, Kawahara H, Kaji A, Katayama K, Mitsuhashi J, Sugimoto Y: Substrate-dependent bidirectional modulation of P-glycoprotein-mediated drug resistance by erlotinib. Cancer Sci. 2009 Sep;100(9):1701-7. doi: 10.1111/j.1349-7006.2009.01213.x. Epub 2009 May 12. [PubMed:19493273 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Transporter activity
Specific Function:
Mediates export of organic anions and drugs from the cytoplasm. Mediates ATP-dependent transport of glutathione and glutathione conjugates, leukotriene C4, estradiol-17-beta-o-glucuronide, methotrexate, antiviral drugs and other xenobiotics. Confers resistance to anticancer drugs. Hydrolyzes ATP with low efficiency.
Gene Name:
ABCC1
Uniprot ID:
P33527
Molecular Weight:
171589.5 Da
References
  1. Heijn M, Hooijberg JH, Scheffer GL, Szabo G, Westerhoff HV, Lankelma J: Anthracyclines modulate multidrug resistance protein (MRP) mediated organic anion transport. Biochim Biophys Acta. 1997 May 22;1326(1):12-22. [PubMed:9188796 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Atpase activity, coupled to transmembrane movement of substances
Specific Function:
ATP-dependent transporter probably involved in cellular detoxification through lipophilic anion extrusion.
Gene Name:
ABCC10
Uniprot ID:
Q5T3U5
Molecular Weight:
161627.375 Da
References
  1. Chen ZS, Hopper-Borge E, Belinsky MG, Shchaveleva I, Kotova E, Kruh GD: Characterization of the transport properties of human multidrug resistance protein 7 (MRP7, ABCC10). Mol Pharmacol. 2003 Feb;63(2):351-8. [PubMed:12527806 ]
  2. Zhou Y, Hopper-Borge E, Shen T, Huang XC, Shi Z, Kuang YH, Furukawa T, Akiyama S, Peng XX, Ashby CR Jr, Chen X, Kruh GD, Chen ZS: Cepharanthine is a potent reversal agent for MRP7(ABCC10)-mediated multidrug resistance. Biochem Pharmacol. 2009 Mar 15;77(6):993-1001. doi: 10.1016/j.bcp.2008.12.005. Epub 2008 Dec 25. [PubMed:19150344 ]
  3. Hopper-Borge E, Xu X, Shen T, Shi Z, Chen ZS, Kruh GD: Human multidrug resistance protein 7 (ABCC10) is a resistance factor for nucleoside analogues and epothilone B. Cancer Res. 2009 Jan 1;69(1):178-84. doi: 10.1158/0008-5472.CAN-08-1420. [PubMed:19118001 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent uptake of organic anions such as 17-beta-glucuronosyl estradiol, taurocholate, triiodothyronine (T3), leukotriene C4, dehydroepiandrosterone sulfate (DHEAS), methotrexate and sulfobromophthalein (BSP). Involved in the clearance of bile acids and organic anions from the liver.
Gene Name:
SLCO1B3
Uniprot ID:
Q9NPD5
Molecular Weight:
77402.175 Da
References
  1. Smith NF, Acharya MR, Desai N, Figg WD, Sparreboom A: Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. Cancer Biol Ther. 2005 Aug;4(8):815-8. [PubMed:16210916 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from t...
Gene Name:
ABCG2
Uniprot ID:
Q9UNQ0
Molecular Weight:
72313.47 Da
References
  1. Fellner S, Bauer B, Miller DS, Schaffrik M, Fankhanel M, Spruss T, Bernhardt G, Graeff C, Farber L, Gschaidmeier H, Buschauer A, Fricker G: Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. J Clin Invest. 2002 Nov;110(9):1309-18. [PubMed:12417570 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Organic anion transmembrane transporter activity
Specific Function:
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name:
ABCC2
Uniprot ID:
Q92887
Molecular Weight:
174205.64 Da
References
  1. Fellner S, Bauer B, Miller DS, Schaffrik M, Fankhanel M, Spruss T, Bernhardt G, Graeff C, Farber L, Gschaidmeier H, Buschauer A, Fricker G: Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. J Clin Invest. 2002 Nov;110(9):1309-18. [PubMed:12417570 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 28, 2016 02:26